Nicox and Ocumension partner to develop and commercialise glaucoma drug
French ophthalmology firm Nicox has collaborated with China-based Ocumension Therapeutics to create and popularize its NCX 470 for the treatment of patients with glaucoma or visual hypertension. NCX 470 is intended to convey bimatoprost and nitric oxide to diminish intraocular pressure (IOP) in patients with open-point glaucoma drug market and visual hypertension. The accomplices consented to a permit arrangement furnishing Ocumension with elite freedoms to NCX 470 in a region that involves central area China, Hong Kong, Macau and Taiwan. Thusly, the Chinese firm will pay €3m forthright to Nicox, which will get extra €2.5m after starting a Phase III clinical preliminary of NCX 470 external the concurred region. Under the particulars of the arrangement, Nicox is additionally qualified to get up to €14.5m in achievements connected to Ocumension's advancement with NCX 470, as well as €16.25m more than three separate deals achievements related with expected deals in the domain of up t...